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Hepatitis C virus (HCV) is an enveloped 
positive-stranded RNA virus of approxi-
mately 9.6 kb that belongs to the Flaviviridae 
family (Suzuki et al., 2007). HCV infection is 
a global health problem affecting nearly 200 
million people (Lauer and Walker, 2001). 
The infection causes prolonged and per-
sistent disease in over half of viral carriers 
that often leads to chronic hepatitis, cirrho-
sis, and hepatocellular carcinoma (Afdhal, 
2004). Recent studies have suggested that 
HCV infects not only hepatocytes but also 
peripheral mononuclear lymphocytes, 
particularly B cells, which express CD81, 
a widely expressed tetraspanin molecule. 
CD81 has been shown to interact with the 
E2 region of HCV envelope proteins (Pileri 
et al., 1998) and is thus regarded as one of 
the key molecules involved in HCV infec-
tion. HCV infection of B cells is the likely 
cause of various B cell dysregulation dis-
orders. Herein, we propose that HCV uses 
peripheral B cells as reservoirs for persistent 
infection, which are in turn responsible for 
HCV pathogenesis.
Although the liver is considered the pri-
mary and main target of HCV infection, 
extrahepatic manifestations such as mixed 
cryoglobulinemia, a systemic immune 
complex-mediated disorder characterized 
by B cell proliferation that may evolve into 
overt B cell non-Hodgkin’s lymphoma 
(B-NHL), are often recognized among 
patients persistently infected with HCV 
(Agnello et al., 1992; Zuckerman et al., 
1997). Epidemiological evidence strongly 
suggests a close association between chronic 
HCV infection and B-NHL occurrence 
(Turner et al., 2003; de Sanjose et al., 2008). 
A pathogenic role of HCV in B cell disorders 
has been further demonstrated by studies 
in which the clinical resolution of B cell 
dysfunctions was observed after successful 
regimens of anti-HCV treatment (Mazzaro 
et al., 1996; Agnello et al., 2002). Based on the 
aforementioned data, Antonelli et al. (2008) 
postulated a role of B cells in HCV patho-
genesis. In accordance with this notion, 
our recent study clearly demonstrated 
papers also favored the notion of HCV 
lymphotropism (Ducoulombier et al., 
2004; Blackard et al., 2006; Pal et al., 2006). 
Figure 1 illustrates the possible process of 
HCV infection in B cells based on previous 
studies using human hepatocyte-derived 
cell lines (Burlone and Budkowska, 2009; 
Georgel et al., 2010). Among B cell sub-
sets, memory B cells are assumed to be 
the main reservoirs of HCV infection pri-
marily because of their long lifespans. In 
support of this notion, our recent study 
indicated that CD19
+ CD27+ cells (i.e., 
memory B cell phenotype) express a high 
amount of CXCR3, a chemokine receptor, 
and are recruited to the inflammatory site 
in the liver of CHC patients where IFN-
γ-inducible protein-10, a CXCR3 ligand, 
is highly produced (Mizuochi et al., 2010; 
Figure 1). This unique strategy seems to 
that HCV infects and may replicate in the 
peripheral CD19+ B cells of chronic hepa-
titis C (CHC) patients (Ito et al., 2010a). 
In order to determine how HCV evades 
antiviral innate immune responses that are 
normally induced in B cells, we analyzed 
expression levels of IFN-β in peripheral B 
cells of CHC patients because type I IFN 
plays a critical role in the antiviral innate 
immune response. We found that HCV 
infection failed to trigger antiviral immune 
responses, such as IFN-β production, in B 
cells of CHC patients (Ito et al., 2010b). This 
suggests that HCV evades antiviral innate 
immune responses in peripheral B cells and 
uses these cells as reservoirs for its persistent 
infection in the host.
The idea that B cells may serve as HCV 
reservoirs was advocated by Muller et al. 
(1993). Several subsequently published 
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Figure 1 | Proposed lifecycle of HCV in B cell. The life cycle of the hepatitis C virus (HCV) has several 
specific steps. Virus entry is mediated by the direct interaction of envelope glycoproteins with co-receptors, 
presumably E2–CD81 binding. CLDN1 and SR-BI are not expressed in B cell. Innate immunity response 
against HCV is suppressed by HCV infection. Some HCV-encoding proteins, i.e., core and NS3, have been 
proven to be expressed in B cells. HCV RNA replication was examined by nested PCR and in situ 
hybridization. Mechanisms of virus assembly, vesicle fusion, and virion release in B cell remain unknown. 
LDLR, low-density lipoprotein receptor; SR-BI, scavenger receptor class B type I; SR-BII, scavenger 
receptor class B type II; CLDN1, claudin-1; OCLN, occludin; CXCR3, chemokine (C-X-C motif) receptor 3; 
IP-10, interferon gamma-induced protein-10.
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persistent infection. HCV may search for 
reservoir sites in cellular compartments 
other than hepatocytes in case the liver 
becomes unsuitable for HCV replication, 
perhaps because of cellular destruction 
caused by the host immune response and/
or by irrelevant conditions for successful 
virus replication, such as the development 
of cirrhosis or hepatocellular carcinoma.
At least two important issues remain to 
be investigated. First, how do HCV-infected 
B cells evade “acquired/adaptive” immune 
responses represented by cytotoxic T cells 
(CTL)? In peripheral blood, the frequen-
cies of HCV-specific CD8+ lymphocytes 
with persistent HCV infection are lower 
than those with acute HCV infection. 
Furthermore, the CTL response to the 
HCV antigen is impaired in chronic HCV 
patients (Lechner et al., 2000). Interestingly, 
the percentage of CTL in peripheral blood 
is lower than that in the liver, which may be 
advantageous for persistent HCV infection 
in B cells. Because the peripheral B cells 
of CHC patients express the HCV core as 
well as NS3 antigens (Ito et al., 2010a), both 
of which encode functional CTL epitopes 
(Hiroishi et al., 2010), it is possible that 
HCV-infected B cells are eliminated by CTL 
to some extent. However, the fact that sub-
stantial amounts of HCV-infected B cells 
are found in CHC patients suggests incom-
plete elimination by CTL by an inhibitory 
mechanism, i.e., HCV E2-mediated inhi-
bition of IL-2/IFN-γ secretion (Petrovic 
et al., 2011). Second, do HCV-infected B 
cells produce infectious HCV? Stamataki 
et al. (2009) demonstrated that the infec-
tious JFH-1 strain of HCV can bind B cells 
but fails to establish productive infection. 
On the other hand, Inokuchi et al. (2009) 
recently demonstrated the presence of neg-
ative-stranded HCV RNA, a marker of viral 
replication, in B cells from 4 of 75 (5%) 
CHC patients. These results support the 
notion that HCV replicates in B cells and 
suggest that infectious HCV are produced 
in B cells. We have currently been investi-
gating this intriguing issue by using an in 
vitro assay system.
In conclusion, lymphoid reservoirs of 
HCV infection may play a role in viral per-
sistence and thereby be involved in its patho-
genesis. Infection and replication of HCV in 
peripheral B cells should be regarded as a 
considerable impediment to the treatment 
of CHC patients undergoing various antivi-
ral regimens. From a therapeutic viewpoint, 
it may be beneficial to eliminate peripheral 
B cells in CHC patients by administering 
anti-B cell antibodies, such as rituximab, 
along with combination chemotherapy of 
peg-IFN-α and ribavirin, which eliminate 
circulating HCV in the blood. Together, this 
could lead to a synergistic effect on HCV 
clearance in CHC patients.
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